BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 27178315)

  • 1. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet.
    Lussier DM; Woolf EC; Johnson JL; Brooks KS; Blattman JN; Scheck AC
    BMC Cancer; 2016 May; 16():310. PubMed ID: 27178315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
    Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
    Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
    Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
    Mathios D; Park CK; Marcus WD; Alter S; Rhode PR; Jeng EK; Wong HC; Pardoll DM; Lim M
    Int J Cancer; 2016 Jan; 138(1):187-94. PubMed ID: 26174883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.
    Shibahara I; Saito R; Zhang R; Chonan M; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Kanehira M; Kikuchi T; So T; Watanabe T; Takahashi H; Iwabuchi E; Tanaka Y; Shibahara Y; Sasano H; Ishii N; Tominaga T
    Mol Cancer; 2015 Feb; 14():41. PubMed ID: 25744203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.
    Wei J; Nduom EK; Kong LY; Hashimoto Y; Xu S; Gabrusiewicz K; Ling X; Huang N; Qiao W; Zhou S; Ivan C; Fuller GN; Gilbert MR; Overwijk W; Calin GA; Heimberger AB
    Neuro Oncol; 2016 May; 18(5):639-48. PubMed ID: 26658052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.
    Wang X; Wang T; Xu M; Xiao L; Luo Y; Huang W; Zhang Y; Geng W
    Hum Immunol; 2014 Dec; 75(12):1203-9. PubMed ID: 25446402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma.
    Murphy KA; Erickson JR; Johnson CS; Seiler CE; Bedi J; Hu P; Pluhar GE; Epstein AL; Ohlfest JR
    J Immunol; 2014 Jan; 192(1):224-33. PubMed ID: 24293627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.
    Berghuis D; Santos SJ; Baelde HJ; Taminiau AH; Egeler RM; Schilham MW; Hogendoorn PC; Lankester AC
    J Pathol; 2011 Feb; 223(3):347-57. PubMed ID: 21171080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.
    Authier A; Farrand KJ; Broadley KW; Ancelet LR; Hunn MK; Stone S; McConnell MJ; Hermans IF
    Int J Cancer; 2015 Jun; 136(11):2566-78. PubMed ID: 25363661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
    Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
    Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade.
    Dejaegher J; Verschuere T; Vercalsteren E; Boon L; Cremer J; Sciot R; Van Gool SW; De Vleeschouwer S
    Int J Cancer; 2017 Nov; 141(9):1891-1900. PubMed ID: 28681455
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Shevtsov M; Pitkin E; Ischenko A; Stangl S; Khachatryan W; Galibin O; Edmond S; Lobinger D; Multhoff G
    Front Immunol; 2019; 10():454. PubMed ID: 30967859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomes from murine-derived GL26 cells promote glioblastoma tumor growth by reducing number and function of CD8+T cells.
    Liu ZM; Wang YB; Yuan XH
    Asian Pac J Cancer Prev; 2013; 14(1):309-14. PubMed ID: 23534743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.
    Yuan X; Hu J; Belladonna ML; Black KL; Yu JS
    Cancer Res; 2006 Mar; 66(5):2630-8. PubMed ID: 16510582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein.
    Crane CA; Han SJ; Ahn B; Oehlke J; Kivett V; Fedoroff A; Butowski N; Chang SM; Clarke J; Berger MS; McDermott MW; Prados MD; Parsa AT
    Clin Cancer Res; 2013 Jan; 19(1):205-14. PubMed ID: 22872572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of HLA-II related to LAG-3
    Guo W; Peng D; Liao Y; Lou L; Guo M; Li C; Yu W; Tian X; Wang G; Lv P; Zuo J; Shen H; Li Y
    Cancer Sci; 2024 May; 115(5):1388-1404. PubMed ID: 38480275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.